PT  - JOURNAL ARTICLE
AU  - Maleki, Kimia T.
AU  - Niemetz, Linda
AU  - Christ, Wanda
AU  - Wigren Byström, Julia
AU  - Thunberg, Therese
AU  - Ahlm, Clas
AU  - Klingström, Jonas
TI  - IL-6 trans-signaling mediates cytokine secretion and barrier dysfunction in hantavirus infected cells and correlate to severity in HFRS
AID  - 10.1101/2024.08.15.24312051
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.15.24312051
4099  - http://medrxiv.org/content/early/2024/08/17/2024.08.15.24312051.short
4100  - http://medrxiv.org/content/early/2024/08/17/2024.08.15.24312051.full
AB  - Background Hantavirus causes hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Strong inflammatory responses and vascular leakage are important hallmarks of these often fatal diseases. The mechanism behind pathogenesis is unknown and no specific treatment is available. IL-6 was recently highlighted as a biomarker for HPS/HFRS severity. IL-6 signaling is complex and context dependent: while classical signaling generally provide protective responses, trans-signaling can cause severe pathogenic responses. This study aims to investigate a potential role for IL-6 trans-signaling in hantavirus pathogenesis.Methods Effects of IL-6 trans-signaling during in vitro hantavirus infection were assessed using primary human endothelial cells treated with recombinant soluble IL-6 receptor (sIL-6R). Plasma from Puumala orthohantavirus-infected HFRS patients (n=28) were analyzed for IL-6 trans-signaling potential and its associations to severity.Findings In vitro, sIL-6R treatment of infected cells enhanced IL-6 and CCL2 secretion, upregulated ICAM-1, and affected VE-cadherin leading to a disrupted cell barrier integrity. HFRS patients showed altered plasma levels of sIL-6R and soluble gp130 (sgp130) resulting in an increased sIL-6R/sgp130 ratio suggesting enhanced IL-6 trans-signaling potential. Plasma sgp130 levels negatively correlated with number of interventions and positively with albumin levels. Patients receiving oxygen treatment displayed a higher sIL-6R/sgp130 ratio compared to patients that did not.Interpretation IL-6 trans-signaling is linked to hantavirus pathogenesis. Targeting IL-6 trans-signaling might provide a therapeutic strategy for treatment of HPS and severe HFRS.Evidence before this study IL-6 have dual effects, it provides important antiviral responses but can also cause severe pathogenesis. IL-6 mediated effects are activated by two different mechanisms, classical signaling and trans-signaling. IL-6 trans-signaling have recently been shown to be responsible for IL-6 mediated pathogenesis. Endothelial cells lack membrane-bound IL-6 receptor and only respond to IL-6 trans-signaling. Orthohantaviruses cause hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS; also called hantavirus cardiopulmonary syndrome (HCPS)), acute severe zoonotic diseases with high fatality rates for which specific treatments and vaccines are lacking. Deregulated vascular permeability and inflammation are hallmarks of HPS and severe HFRS. However, the mechanisms underlying hantavirus disease are unknown, hampering the development of treatments. Orthohantaviruses primarily infect endothelial cells. Previous studies have demonstrated a correlation between elevated IL-6 levels and increased severity of HPS and HFRS. Whether this link is causal, and if so the mechanisms behind it, has not been determined.Added value of this study This study demonstrates that hantavirus-infected endothelial cells produce large amounts of IL-6, and are highly sensitive to IL-6 trans-signaling mechanisms. Together this strongly amplifies the IL-6 production and disrupt the endothelial cell barrier causing severe fluid leakage. When analyzing a potential role for IL-6 trans-signaling in patients, we observed increased systemic IL-6 trans-signaling potential, and that this was linked to severity, in Puumala virus-infected HFRS patients.Implications of all the available evidence These data suggest the two hallmarks of HPS and HFRS; increased vascular permeability and strong inflammation, is linked via hantavirus-induced endothelial cell IL-6 production and IL-6 trans-signaling effects. Treatment targeting IL-6 trans-signaling might provide a therapeutic strategy for HPS and severe HFRS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementC. Ahlm received fundings from Region Vasterbotten and Umea University, project numbers RV-579011, RV-734361, and RV-965866, and from the Heart-Lung Foundation, project numbers 20170334 and 20150752. J. Klingstrom received fundings from the Swedish Research Council, project number 2018-02646, and from the center for medical innovation (CIMED), project number 2020-0141.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Regional Ethics Committee of Umea University (application number 04-133M).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript